Great Novel Therapeutics Biotech & Medicals (ROCO:7427) ROCE %: -19.55% (As of Dec. 2025)


ROCO:7427 Great Novel Therapeutics Biotech & Medicals ROCO:7427
49 GF Score
Price NT$39.65
GF Value NT$25.61
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Great Novel Therapeutics Biotech & Medicals ROCE %?

Great Novel Therapeutics Biotech & Medicals ROCO:7427 -1.25% 49 ROCE % is -19.55% as of Dec. 2025. GuruFocus rates ROCO:7427 with a GF Score™ of 49/100 and a GF Value™ of NT$25.61 (Significantly Overvalued). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Great Novel Therapeutics Biotech & Medicals's annualized ROCE % for the quarter that ended in Dec. 2025 was -19.55%.

Great Novel Therapeutics Biotech & Medicals  (ROCO:7427) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Great Novel Therapeutics Biotech & Medicals ROCE % Related Terms

Great Novel Therapeutics Biotech & Medicals ROCE % Historical Data

* Premium members only.

The historical data trend for Great Novel Therapeutics Biotech & Medicals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Great Novel Therapeutics Biotech & Medicals ROCE % Chart

Great Novel Therapeutics Biotech & Medicals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial -22.21 -19.60 -13.44 -17.67 -16.96

Great Novel Therapeutics Biotech & Medicals Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.47 -20.21 -13.00 -14.78 -19.55
ROCO:7427
49GF Score
Great Novel Therapeutics Biotech & Medicals ROCO:7427
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Great Novel Therapeutics Biotech & Medicals ROCE % Calculation

Great Novel Therapeutics Biotech & Medicals's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-97.376/( ( (662.6 - 21.823) + (526.752 - 19.337) )/ 2 )
=-97.376/( (640.777+507.415)/ 2 )
=-97.376/574.096
=-16.96 %

Great Novel Therapeutics Biotech & Medicals's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-105.284/( ( (587.173 - 17.336) + (526.752 - 19.337) )/ 2 )
=-105.284/( ( 569.837 + 507.415 )/ 2 )
=-105.284/538.626
=-19.55 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -19.55% mean?
Great Novel Therapeutics Biotech & Medicals (ROCO:7427) has a ROCE % of -19.55% as of Dec. 2025.
Is Great Novel Therapeutics Biotech & Medicals' ROCE % too high?
Great Novel Therapeutics Biotech & Medicals' current ROCE % is -19.55%. Overall, Great Novel Therapeutics Biotech & Medicals has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Great Novel Therapeutics Biotech & Medicals' ROCE % compare to VRTX and REGN?
Great Novel Therapeutics Biotech & Medicals' ROCE % of -19.55% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Great Novel Therapeutics Biotech & Medicals's current ROCE % is -19.55%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Great Novel Therapeutics Biotech & Medicals stock overvalued right now?
Based on GuruFocus' analysis, Great Novel Therapeutics Biotech & Medicals (ROCO:7427) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$25.61, compared to a current price of NT$39.65 — trading 54.8% above its estimated fair value. The current ROCE % is -19.55%. Great Novel Therapeutics Biotech & Medicals' overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Great Novel Therapeutics Biotech & Medicals (ROCO:7427), the current ROCE % is -19.55% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Overvalued in 2026?

Based on GuruFocus' analysis, Great Novel Therapeutics Biotech & Medicals stock appears to be overvalued. The current stock price of NT$39.65 is trading 54.8% above its estimated GF Value™ of NT$25.61. GuruFocus considers Great Novel Therapeutics Biotech & Medicals to be Significantly Overvalued.

Key valuation signals for ROCO:7427:

  • ROCE %: -19.55%
  • GF Value™: NT$25.61 vs. price of NT$39.65 (54.8% above fair value)
  • GF Score™: 49/100 with 3 warning signs

No single metric tells the full story. See the ROCO:7427 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Great Novel Therapeutics Biotech & Medicals Business Description

Address No.3, Park Street, Room WR-06, 17th Floor, Nangang District, Taipei, TWN, 11503
Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.
49GF Score

Get the complete analysis for ROCO:7427

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$39.65
Price
NT$25.61
GF Value